Sustained urokinase-type plasminogen activator (uPA) expression is detected in aggressive breast tumors. Although uPA can be transiently upregulated by diverse extracellular stimuli, sustained, but not transiently upregulated uPA expression contributes to breast cancer invasion/metastasis. Unfortunately, how sustained uPA expression is achieved in invasive/metastatic breast cancer cells is unknown. Here, we show that sustained and transiently upregulated uPA expression are regulated by distinct mechanisms. Using a collection of transcription factor-targeted small-interfering RNAs, we discovered that interleukin enhancer-binding factor 3 (ILF3) is required for sustained uPA expression. Two discrete mechanisms mediate ILF3 action. The first is that ILF3 activates uPA transcription by binding to the CTGTT sequence in the nucleotides À 1004B À 1000 of the uPA promoter; the second is that ILF3 inhibits the processing of uPA mRNA-targeting primary microRNAs (pri-miRNAs). Knockdown of ILF3 led to significant reduction in in vitro cell growth/migration/invasion and in vivo breast tumor development. Importantly, immunohistochemistry (IHC) showed that nuclear ILF3, but not cytoplasmic ILF3 staining correlates with elevated uPA level and higher grades of human breast tumor specimens. Nuclear localization of ILF3 highlights the role of ILF3 in sustained uPA expression as a transcription activator and pri-miRNA processing blocker. In conclusion, this study shows that ILF3 promotes breast tumorigenicity by regulating sustained uPA expression.
INTRODUCTION
The fibrinolytic system, consisting of urokinase-type plasminogen activator (uPA), its receptor (uPAR) and plasminogen activator inhibitors (PAI-1 and PAI-2), is actively involved at multiple stages of tumor progression. Binding of uPA to uPAR triggers the conversion of plasminogen to plasmin and the subsequent activation of metalloproteinases. These events confer tumor cells with the capability to degrade the components of the surrounding extracellular matrix, thus contributing to tumor cell invasion/ metastasis. 1 uPA-uPAR interaction also elicits signals that stimulate cell migration, cell proliferation/survival and the expression of tumor-promoting genes, thereby further facilitating tumor development. 2 uPA level is elevated in various metastatic tumors. 3 In breast cancer, high uPA level correlates with tumor aggressiveness and poor patient survival. 4 Together with PAI-1, uPA level in breast tumor tissues is used as a prognostic marker. 5 uPA expression can be induced in breast cancer cells by growth factors and phorbol ester. [6] [7] [8] However, such induction is transient and lasts only for a short period of time. AP1-and/or nuclear factor-kappaB-dependent mechanisms have been shown to mediate the transient uPA upregulation. 9 On the contrary, invasive/metastatic breast cancer cells exhibit sustained uPA expression 10, 11 though uPA level can be further transiently elevated by extracellular stimuli in them. [6] [7] [8] It is well recognized that cancer cells necessitate sustained, rather than transiently induced uPA expression for invasion/metastasis. 12 Unfortunately, how sustained uPA expression is achieved in invasive/metastatic cancer cells is unknown.
Members of interleukin enhancer-binding factor 3 (ILF3) family were originally purified from a protein complex that regulates interleukin-2 transcription. [13] [14] [15] Members of this family, namely NF90a, NF90b, NF110a and NF110b, are the products of differential splicing of ILF3 transcripts. 16 They are identical at the N-terminal and central regions but diverge at their C-terminal regions. 17 Through the ability to bind both DNA and RNA, 16 members of ILF3 can regulate transcription, 15, 18 translation, 19, 20 mRNA stability 21, 22 and primary microRNA (primiRNA) processing. 23 The observation that ILF3 is overexpressed in nasopharyngeal carcinoma, non-small cell lung carcinoma and ovarian cancer [24] [25] [26] indicates that ILF3 is potentially involved in oncogenesis. This possibility is supported by an early study in which ILF3 was shown to promote angiogenesis through the stabilization of vascular endothelial growth factor mRNA. 21 The objective of this study is to elucidate the mechanism responsible for sustained uPA expression in breast cancer cells. Using MDA-MB-231 line, we screened a collection of smallinterfering RNAs (siRNAs) that target 1294 transcription factors. Among identified targets, ILF3 was specifically required for sustained uPA expression in breast cancer cells. Two discrete mechanisms mediate ILF3 action. The first is that ILF3 binds to the CTGTT sequence at nucleotides À 1004B À 1000 of the uPA promoter to activate uPA transcription. The second is that ILF3 inhibits the processing of uPA mRNA-targeting pri-miRNAs. Moreover, we found that depleting ILF3 suppressed both in vitro and in vivo breast tumorigenicity. Finally, we showed that enhanced nuclear ILF3 staining correlated with the uPA overexpression and higher tumor grade in breast tumor specimens.
RESULTS
Sustained and transiently upregulated uPA expression are regulated by distinct mechanisms Both uPA mRNA and protein were expressed at high levels in invasive, but not in less-invasive breast cancer cell lines (Figures 1a-c) and knockdown of uPA led to significant reduction in in vitro invasion of invasive breast cancer cells (Supplementary Figure S1) . Interestingly, phorbol 12-myristate 13-acetate (PMA) transiently upregulated uPA level in both invasive (MDA-MB-231, MDA-MB-436) and less-invasive breast cancer cells (T47D) in a similar fashion (Figure 1d ). Treatment with conventional protein kinase C (cPKC) inhibitor Gó 6976 and MEK1/2 inhibitor U0126 before PMA stimulation largely abolished PMA-induced uPA upregulation in all three cell lines (Figure 1e ). In contrast, these inhibitors displayed little to slight inhibitory effect on the sustained uPA expression in invasive lines (Figure 1f ). These results indicate that sustained and transiently upregulated uPA expression may be regulated by distinct mechanisms.
ILF3 is specifically required for sustained uPA expression To define the mechanism important for sustained level of uPA, we first compared uPA transcription between invasive and less-invasive breast cancer cell lines by performing chromatin immunoprecipitation (ChIP) with RNA polymerase II (RP-II) pAb. Quantitative PCR (qPCR) showed that uPA promoter sequence was enriched at least eight-fold more in the RP-II ChIPs when compared with that in control IgG ChIPs in invasive breast cancer lines ( Figure 2a) ; whereas barely any increase was detected in less-invasive lines (Figure 2a ), indicating that sustained uPA expression is regulated at the level of uPA transcription in breast cancer cells. To identify transcription factor(s) pertinent to sustained uPA expression, MDA-MB-231 cells were individually transfected with a collection of 1294 siRNAs that target most of the known transcription factors in human followed by In-Cell Western assay to detect uPA (Supplementary Figure S2A) . Through this screening, five siRNAs that target Ets-1, ILF3, c-Jun, NF45 and STAT1 were found to downregulate uPA level (Figure 2b and Supplementary Table S1 ). To validate theses targets, MDA-MB-231 cells were transfected with two distinct siRNAs for each target. Immunoblotting showed that knockdown of ILF3 or NF45 led to over 80% reduction in uPA expression, whereas Ets-1, c-Jun and STAT1 siRNA only moderately reduced uPA level compared with the scrambled siRNA control (Figure 2c) . Similarly, knockdown of ILF3 or NF45 reduced approximately 80% of uPA promoter activity (Supplementary Figure S2B) . These results suggest that ILF3 and NF45 are the crucial transcription factors for sustained uPA expression. ILF3 gene products including NF90a/b and NF110a/b are known to regulate gene expression together with NF45. 15, [18] [19] [20] [21] [22] [23] 27 We further determined the importance of ILF3 and NF45 in sustained uPA expression by lentivirally introducing two distinct ILF3 or NF45 short hairpin RNAs (shRNAs) into MDA-MB-231 and MDA-MB-436 cells. Both ILF3 shRNAs not only reduced ILF3 but also NF45 level while depleting NF45 also reduced both uPA and ILF3 levels ( Figure 3a) . These results are in line with the earlier study showing that the stability of ILF3 and NF45 proteins requires stable interaction among them. 27 The inhibitory effect on uPA expression caused by ILF3 or NF45 knockdown was relatively specific because the level of cyclooxygenase-2, a protein highly expressed in invasive breast cancer cells, was little affected (Figure 3a) . Moreover, PMA transiently upregulated uPA expression in ILF3-knockdown cells in a similar fashion as seen in the respective parental cells (compare Figure 3b with Figure 1d ). These results suggest that ILF3/NF45 complex is required for sustained uPA expression.
As our designed ILF3 shRNAs target all splicing isoforms of ILF3, we examined the relevance of individual ILF3 members by expressing shRNA-refractory NF90a, NF90b, NF110a or NF110b in ILF3-knockdown cells either individually or together. Immunoblotting showed that uPA expression was rescued only when all isoforms were expressed in knockdown cells (Figure 3c ). These results coincide with the observation that silencing either NF90 or NF110 led to significant reduction in uPA mRNA as well as protein in MDA-MB-231and MDA-MB-436 cells (Figures 3d and e) .
Together, these results suggest that both NF90 and NF110 are indispensable for sustained uPA expression.
ILF3 activates uPA transcription As knockdown of ILF3 resulted in reduced steady-state uPA mRNA level in breast cancer cells (Figure 3d) , we examined the effect of ILF3 depletion on both uPA transcription and mRNA stability in MDA-MB-231 and MDA-MB-436 cells. ChIP with RP-II pAb showed that depletion of ILF3 reduced the uPA promoter occupancy of RP-II by more than 80% (Supplementary Figure S3A) . Analysis with uPA promoter-containing luciferase reporter plasmid further showed that knockdown of ILF3 decreased luciferase activity to similar extent when compared with negative control (Figure 4a ). In contrast, actinomycin-chasing experiment showed that knockdown of ILF3 did not significantly alter the half-life of uPA mRNA in these cells (Supplementary Figure S3B) . These results suggest that ILF3 regulates uPA transcription in breast cancer cells.
To identify the region in uPA promoter important for sustained uPA transcription in breast cancer cells, we generated a series of uPA promoter deletion constructs (Figure 4b ). Luciferase activity analysis showed that region between nucleotides À 1072B À 859 contained sequences essential for sustained uPA promoter activity in invasive breast cancer cell lines (Figure 4b and Supplementary Figure S4A ). On the basis of the previously identified consensus ILF3-binding sequence CTGTT (or AACAG in antisense direction), 15, 18 there are two consensus sequences at nucleotides À 978B À 982 and À 1004B À 1000 in this region ( Figure 4c ). Mutagenesis at these two sites and an additional site outside of this region followed by luciferase activity assay showed that only sequence at nucleotides À 1004B À 1000 was essential and responsible for uPA promoter activity ( Figure 4c ). These results indicate that ILF3 activates uPA transcription through ILF3 consensus sequence at nucleotides À 1004B À 1000 in the uPA promoter. This observation is further supported by the observation that ILF3 depletion did not further reduce the luciferase activity of promoter having mutation at nucleotides À 1004B À 1000 (Supplementary Figure S4B) . Subsequently, we also investigated the effect of mutating ILF3-or AP1/NFkB-binding site in PMA-induced uPA promoter activity. PMA greatly elevated lucifease activity in cells transfected with uPA promoter reporter plasmid containing mutation in ILF3-binding site ( Figure 4d ). However, PMA-elevated luciferase activity was not seen in uPA promoter reporter plasmid with mutation in AP1/NFkB-binding site ( Figure 4d ). These results show that sustained and transiently upregulated uPA transcriptions are respectively regulated by ILF3-and AP1/NFkB-dependent mechanisms in breast cancer cells.
To further corroborate transcriptional regulation of uPA by ILF3, we synthesized oligonucleode spanning nucleotides À 1013B À 969 of the uPA promoter. Electrophoretic mobility shift assay with 32 P-labeled oligonucleotides showed that 32 P-labeled oligonucleode/protein complex was seen in the nuclear extracts of parental and shRNA control-transduced MDA-MB-231 and MDA-MB-436 cells, whereas it was absent in ILF3-knockdown cells (Figure 4e ). The formation of 32 P-labeled oligonucleode/ protein complex was diminished by the excess of unlabeled wildtype oligonucleotide but not oligonucleode containing mutation at CTGTT site (Figure 4f ). In parallel, we investigated in vivo ILF3-uPA promoter interaction by ChIP using ILF3 pAb. qPCR with the primers specifically amplifying region containing ILF3-binding site (nucleotides À 1037B À 935) showed that this region was enriched more than 10-fold in ILF3 immunoprecipitates over the IgG control (Figure 4g ). However, such enrichment was not detected in ILF3-knockdown cells (Figure 4g ). These results show that ILF3 activates uPA transcription by binding to the CTGTT sequence at nucleotides À 1004B À 1000 of the uPA promoter.
ILF3 contributes to sustained uPA expression by inhibiting the processing of uPA mRNA-targeting pri-miRNAs We previously showed that uPA mRNA is the target of miR-193a, miR-193b and miR-181a in breast cancer cells. 11 As ILF3 can inhibit the production of miRNA by blocking the processing of primiRNA, 23 we hypothesized that ILF3 might also regulate sustained uPA expression by inhibiting the processing of pri-miR-193a/193b/ 181a. To test this possibility, we initially analyzed the levels of priand mature miR-193a/193b/miR-181a in both control and ILF3-knockdown MDA-MB-231 cells. Levels of pri-miR-193a/193b/181a were moderately lower in control than those in ILF3-knockdown cells, whereas the levels of their respective mature miRNAs were greatly increased in ILF3-knockdown cells compared with the control (Figure 5a ). Similar results were also observed with MDA-MB-436 cells (Supplementary Figure S5) . Subsequently, we introduced luciferase reporter plasmid containing 3 0 untranslated region (3 0 -UTR) of uPA mRNA into both control and ILF3-knockdown cells. The luciferase activity was reduced more than 40% in ILF3-knockdown cells compared with that of control (Figure 5b ). However, ILF3 knockdown-caused reduction in luciferase activity was largely reversed by the combined treatment of miR-193a/193b/181a inhibitors (Figure 5c ). Luciferase activity was similar with reporter plasmid containing mutations in P-labeled wildtype oligonucleotide in the presence of 5-40-fold of excess of unlabeled wild-type or mutant oligonucleotides and then subjected to electrophoretic mobility shift assay. (g) Cells were subjected to ChIP with ILF3 pAb. qPCR was performed using primer set that amplifies region spanning nucleotides À 1037B À 935 of the uPA promoter. Data are the mean ± s.e.m., n ¼ 3. Figure S6) . These results indicate that reduced uPA expression is at least partially responsible for decreased cell growth, migration and invasion of ILF3-knockdown cells. In the parallel experiment, we also lentivirally introduced each of the ILF3 members into MDA-MB-231 cells. Cells with stably expressed NF90a, NF90b, NF110a or NF110b all exhibited enhanced in vitro invasion compared with control cells (empty vector) (Supplementary Figure S7) , confirming an invasion-promoting role of ILF3 in breast cancer cells.
We next analyzed the effect of ILF3-knockdown in breast tumor development using the well-established orthotopic breast tumor model. 28, 29 Control or ILF3-knockdown MDA-MB-231 cells (both stably expressing enhanced green fluorescent protein (EGFP) were injected into mammary fat pad area of female athymic nude mice and mice were monitored weekly for 7 weeks by measuring fluorescence. Judging by the fluorescence intensity, mice injected with control cells displayed a much greater tumor outgrowth rate than mice injected with ILF3-knockdown cells (Figure 6d ). Tumors were apparent in all eight mice injected with control cells, whereas significantly smaller tumors were detected in four mice injected with ILF3-knockdown cells after 7 weeks (Figure 6e) . As expected, level of uPA was much less in the tumors excised from mice injected with ILF3-knockdown cells than those in the control (Figure 6f ). When the frozen sections of lungs from these mice were analyzed, EGFP-expressing cells were detected in lungs of seven out of eight control mice but only one out eight mice injected with ILF3 knockdown cells (Figure 6g) . Identical results were obtained with immunoblotting that determined the The intensity of ILF3 nuclear staining correlates with disease grades and uPA expression of breast tumors As laboratory studies may not recapitulate clinical breast cancer, we performed IHC to examine ILF3 level in commercial human tissue arrays that contained 49 breast tumor specimens and 33 normal breast tissues (isolated from area surrounding breast tumors). ILF3 was detected in both cytoplasm and nucleus, and was present in both breast tumors and normal breast tissues (Figure 7a ). There was no significant difference in the level of cytoplasmic ILF3 between breast tumor tissues and normal breast (Figure 7b ). Cytoplasmic ILF3 staining was also not associated with other pathological parameters including age, tumor size (T), lymph node status (N), ER/PR/HER2 status or disease grades (Supplementary Table S2 ).
We next compared the intensity of nuclear ILF3 staining between normal and breast tumor tissues. Nuclear ILF3 staining was strong in 38 of 49 breast tumor specimens but in only 5 of 33 (Figure 7b ). Although the intensity of nuclear ILF3 staining was independent of age, tumor size, ER/PR/HER2 status (Table 1) , it was significantly associated with breast tumor grades ( Table 1) . To determine the association between ILF3 and uPA in clinical breast tumor specimens, we also performed IHC to analyze the level of uPA in the same patients' samples. Although normal breast tissues were negative or weak for uPA staining, 24 of 49 breast tumor specimens were strong for uPA staining (49.0%, Po0.001) (Figure 7a) . Importantly, all specimens with high uPA level displayed strong nuclear ILF3 staining (R ¼ 0.527, Po0.001) (Supplementary Table S3 ). To further investigate ILF3-uPA correlation, we analyzed continuous sections from ten breast tumor tissues. IHC again showed that specimens positive for uPA staining all displayed strong nuclear ILF3 staining while specimens negative for uPA expression exhibited relatively weaker nuclear ILF3 staining although overall cellular ILF3 staining were not significantly different between samples positive and negative for uPA staining (Figure 7c) . These results show a strong correlation between high nuclear ILF3 staining and elevated uPA expression in breast tumor tissues.
DISCUSSION
Sustained high uPA level is detected in both invasive breast cancer cell lines and specimens of aggressive breast tumors. 10, 11, 30 In vitro and in vivo studies clearly demonstrate the importance of sustained uPA expression in breast tumorigenicity. 31 In the MMTVPymT transgenic breast cancer model, uPA deficiency has been shown to reduce metastasis by more than seven-fold. 32 We have also shown that uPA-targeting siRNAs and miRNAs suppressed breast cancer cell invasion. 11 However, how metastasis-pertinent sustained uPA expression is maintained in invasive breast cancer cells is unknown. In breast cancer cells, uPA can be upregulated by diverse stimuli including growth factors and phorbal ester. [6] [7] [8] We showed that PMA transiently upregulated uPA expression in both invasive and less-invasive breast cancer cells in cPKC/Erk-dependent mechanism (Figure 1) . However, sustained uPA expression in invasive breast cancer cells is not significantly affected by cPKC or MEK1/2 inhibitor (Figure 1 ). This observation led us to hypothesize that distinct mechanisms regulate transient and sustained uPA expression. In this study, we identified ILF3 as a key gene specifically involved in sustained uPA expression in invasive breast cancer cells (Figures 2, 3 and 4) . Early studies have shown that Ets-1, nuclear factor-kappaB and AP1 components regulate uPA expression in breast cancer cells. [33] [34] [35] [36] These studies were exclusively done in cells under extracellular stimulation. Our observation that Erk activity was required for PMA-induced transient uPA upregulation suggests that Erk may act through these previously identified transcription factors to mediate PMA action, especially Erk signaling pathway has been shown to regulate the expression of many of these factors in breast cancer cells. [37] [38] [39] Members of ILF3 can regulate gene expression by a variety of mechanisms such as transcription, 15, 18 translation, 19,20 mRNA stability 21, 22 and pri-miRNA processing. 23 Interestingly, we have previously shown that uPA expression can also be regulated at the levels of both transcription and post-transcription. 11, [40] [41] [42] This study shows that ILF3 regulates sustained uPA expression in two discrete mechanisms. In the first, ILF3 directly facilitates uPA expression by activating uPA gene transcription (Figure 4 ). In the second, ILF3 indirectly contributes to sustained uPA expression by suppressing the processing of uPA mRNA-targeting pri-miRNAs ( Figure 5 ). Our studies thus support a unique bi-modal capability of ILF3 in regulating gene expression.
An earlier study has implicated an important role of ILF3 in tumor progression where ILF3 was shown to promote tumor angiogenesis by stabilizing vascular endothelial growth factor mRNA. 21 In this study, we showed that silencing ILF3 led to significant reduction in cell growth, migration and in vitro invasion; however, the addition of single-chain uPA partially reversed the effects of ILF3 knockdown ( Figure 6 ). Our findings thus functionally linked ILF3 to sustained uPA expression in breast tumorigenicity. Moreover, we showed that knockdown of ILF3 greatly diminished breast tumor outgrowth and spontaneous lung metastasis in athymic nude mouse model ( Figure 6 ). Taken together, our study presents strong evidence that ILF3 has a crucial role in breast tumor progression.
Overexpression of ILF3 was reported in nasopharyngeal carcinoma, non-small cell lung carcinoma and ovarian cancer.
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Although we did not detect significant increase in the level of cytoplasmic ILF3 in clinical breast tumor specimens, we observed much stronger nuclear ILF3 staining in breast tumors when compared with normal breast tissues ( Figure 7 ). Elevated nuclear ILF3 staining correlated with high uPA level and higher tumor grade in breast tumor specimens ( Figure 7 , Table 1 and  Supplementary Table S3 ). The nuclear localization ILF3 highlights its role as both transcription factor and pri-miRNA-processing suppressor in the process of maintaining sustained uPA expression in invasive breast cancer cells. Our finding also suggests that attention should be paid to the intracellular localization of ILF3 (nucleus vs cytoplasm), rather than solely on the level of ILF3 when the relevance of ILF3 to tumor development is investigated.
Our mechanistic study was performed with the established breast cancer cell lines that may not fully simulate clinical setting. However, the consistency seen in mouse model and the excellent correlation between nuclear ILF3 staining and uPA level/tumor grades in clinical specimens argue against any confounding influence derived from our experimental studies. To sum up, our studies suggest that ILF3 promotes breast tumorigenicity by maintaining sustained uPA expression in breast cancer cells.
MATERIALS AND METHODS

ShRNAs/siRNAs
ILF3 and NF45 shRNAs were designed using web-based Block-iT program and subcloned into pLV-mU6-(shRNA)-EF1a-GFP vector (Biosettia, San Diego, CA, USA). siRNAs specific for NF90 and NF110 were previously described. 27 ShRNA/siRNA sequences are included in Supplementary Information.
In-Cell Western assay to identify transcription factor important for sustained uPA expression MDA-MB-231 cells were plated at 50 000 cells per well in 96-well plates overnight and then transfected with Dharmacon (Lafayette, CO, USA) siGENOME collection that targets 1294 human transcription factor genes for 3 days followed by fixation. Fixed cells were permeabilized, incubated with uPA mAb/GAPDH pAb and again incubated with infrared probe-labeled secondary antibodies. The intensities of uPA and GAPDH levels were determined by Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Each siRNA was tested in triplicates and reduction of more than 25% in the staining intensity over cells treated with control siRNA was set as the cutoff point.
Cell growth study Cell growth was evaluated by MTT assay as previously described. 43 Briefly, 5 Â 10 4 cells were seeded into 24-well culture plates and allowed to grow for 1-3 days before the addition of MTT. The cell growth rate was determined by reading plates at 560 nm.
Cell migration and in vitro invasion
Cell migration and in vitro invasion were evaluated using Transwells and Matrigel invasion chamber, respectively, as previously described. 37 For cell migration, the undersurfaces of Transwells were coated with 10 mg/ml of collagen and 1 Â 10 5 cells were allowed to migrate for 4 h. For in vitro invasion, 2 Â 10 5 cells were allowed to invade for 24 h. After migration/ invasion, cells on the undersurface of upper units were stained and counted using a phase-contrast microscope.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from cells using Trizol, treated by DNase I and reverse transcribed with either SuperScriptase or TaqMan microRNA reverse transcription Kit (Invitrogen, Carlsbad, CA, USA). Generated products were used to measure the levels of uPA mRNA, pri-miRNA181a/193a/193b and miR-181a/193a/193b using the respective TaqMan probes. Level of b-actin mRNA was measured for standardization.
Luciferase reporter assay
The construction of luciferase reporter plasmids containing human uPA promoter and 3 0 -UTR has been described previously. 11, 41 To map out the region important for sustained uPA promoter activity, sequential deletion was made in uPA promoter by PCR and subsequently inserted into pGL2 vector (Promega, Madison, WI, USA). To determine the importance of putative ILF3 consensus sequences in uPA promoter activity, site-directed mutagenesis was performed using QuickChange site-directed mutagenesis kit (Agilent, Clara, CA, USA). To normalize the difference in the transfection efficiencies with various constructs, plasmid containing pGK promoterdriven Renella luciferase gene (pGK-R/Luc, Promega) was included during the transfection. Reporter's firefly luciferase activities were normalized by dividing the values of Renella luciferase activities.
Electrophoretic mobility shift assay Nuclear extracts were prepared as previously described. 41 Nuclear extracts (10 mg/reaction) were incubated with 32 P-labeled oligonucleotides (1.5 Â 10 5 cpm/reaction) and mixtures were then electrophoresed on a 6% non-denaturing polyacrylamide gel. To determine the specificity of oligonucleotide-nuclear extract complex, up to 40-fold excess of unlabeled oligonucleotides of wild-type or ILF3-binding site mutant were added into the reactions followed by electrophoresis. Oligonucleotide sequences are included in Supplementary Information.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described. 44 To determine uPA transcription and in vivo ILF3-uPA promoter interaction, chromatin fragments were immunoprecipitated with RP-II and ILF3 pAbs, respectively. ILF3 regulation of sustained uPA expression Q Hu et al Rabbit IgG was used as a negative control. uPA promoter sequence enrichment was determined by qPCR using primers amplifying region either near the transcription start site or spanning ILF3-binding site of the uPA promoter. Primer sequences are included in Supplementary Information.
Tumor growth and lung metastasis in nude mice
Animal studies were performed as previously described 37 and were approved by the Georgia Health Sciences University (GHSU) Institutional Animal Care and Use Committee. Briefly, 3 Â 10 6 control or ILF3-knockdown MDA-MB-231 cells (EGFP-expressing) were injected into forth mammary fat pad of 5-week-old female nude mice (Harlan Laboratory, Tampa, FL, USA). Starting from 3rd week, tumor growth was monitored by measuring fluorescence in Xenogen IVIS-200 in vivo imaging system. Seven weeks after injection, animals were killed and both tumors and lungs were excised. Collected tumors were homogenized and analyzed for uPA expression. Parts of excised lungs were frozen and sectioned for detecting EGFP-expressing cells and the remaining was analyzed for EGFP by immunoblotting.
Immunohistochemistry (IHC)
ILF3 and uPA levels in breast tumors and normal breast tissues were evaluated by IHC using anti-ILF3 pAb and anti-uPA mAb on commercial tissue arrays (Shanghai Outdo Biotech, Shanghai, China) as previously described. 45 The array contained 33 normal breast tissues and 49 breast tumor specimens (all were ductal carcinomas of breast). Staining intensity of each sample was given a modified histochemical score (MH-score) that considers both the intensity and the percentage of cells stained at each intensity. 46 Samples with below the average MH-score were considered as no/weak staining while samples with above the average MH-score considered as strong staining. To investigate the correlation between ILF3 and uPA expression in breast tumors, continuous sections were made from breast tumor paraffin blocks that were obtained from GHSU tumor bank and subjected to IHC to detect ILF3 and uPA. Experiments involving human tissues were approved by GHSU Human Assurance Committee.
Statistical analysis
Statistical analyses of laboratory studies were performed by Student's t-test. w 2 test and Fisher's exact test were used to compare correlation between ILF3/uPA staining and clinicopathological parameters. Po0.05 was considered to be significant.
